In melanoma, combining T-VEC, a modified herpes simplex virus, with a MEK inhibitor (trametinib) produced an increased infiltration of CD8+ T cells into the tumor and a decreased tumor size in vivo [14]. This evidence concerns the gene MAP2K7 and neoplasm.